問卷

TPIDB > Search Result

Search Result

篩選

List

106Cases

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2019-06-01 - 2026-12-31

Phase III

Active
An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP)
  • Condition/Disease

    Generalized Pustular Psoriasis (GPP)

  • Test Drug

    Spesolimab (BI 655130)

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-12-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-11-01 - 2024-11-29

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-06-01 - 2024-11-29

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2025-06-01 - 2034-08-15

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-04-01 - 2014-04-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-09-01 - 2011-08-31

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-01-30 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2020-08-01 - 2025-12-04

Phase III

Active
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa
  • Condition/Disease

    Moderate to Severe Hidradenitis Suppurativa

  • Test Drug

    AIN457

Participate Sites
2Sites

Recruiting2Sites